Failure is an Option

Blogger DrugMonkey says that when it comes to NIH grants, a little failure can be a good thing. NIH/CSR review panels seem to be fixated on preliminary data, DrugMonkey says, perhaps because the reviewers think part of their job is to separate the projects that will succeed from those that will fail. But what does it mean to fail?

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.